Last checked at 15 Dec 2023 18:17
Renalytix plc
("Renalytix" or the "Company")
Result of AGM
LONDON and SALT LAKE, 15 December 2023 - Renalytix (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.
The results of the AGM are detailed below:
For | % voted in favour |
| Against | % voted against | Withheld | |
Ordinary resolutions |
| |||||
1 Accept Financial Statements and Statutory Reports | 40,118,702 | 99.94% | 24,743 | 0.06% | 67,418 | |
2 Approve Remuneration Report | 39,959,034 | 99.44% | 226,856 | 0.56% | 24,973 | |
3 Re-elect Cathy Coste | 39,058,428 | 97.29% | 1,086,363 | 2.71% | 66,072 | |
4 Withdrawn | - | - | - | - | - | |
5 Reappoint EY | 39,266,710 | 97.73% | 910,387 | 2.27% | 33,766 | |
6 Reappoint PKF Littlejohn LLP as Auditors | 40,142,582 | 99.91% | 37,614 | 0.09% | 30,667 | |
7 Authorise Board to Fix Remuneration of Auditors | 40,105,519 | 99.81% | 77,729 | 0.19% | 27,615 | |
8 Authorise Issue of Equity | 38,484,392 | 95.78% | 1,697,234 | 4.22% | 29,237 | |
Special resolutions |
| |||||
9 Authorise Issue of Equity without Pre-emptive Rights | 38,467,804 | 95.74% | 1,710,946 | 4.26% | 32,113 | |
10 Authorise Market Purchase of Ordinary Shares | 39,597,340 | 99.87% | 51,284 | 0.13% | 562,239 | |
11 Adoption of new articles | 40,059,859 | 99.74% | 104,681 | 0.26% | 46,323 |
For further information, please contact:
Renalytix plc? | www.renalytix.com | |
James McCullough, CEO | Via Walbrook PR | |
Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 | |
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea | ||
Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 | |
Gary Clarence / Shalin Bhamra | ||
Walbrook PR?Limited | Tel: 020 7933 8780 or?renalytix@walbrookpr.com | |
Paul McManus / Alice Woodings / Charlotte Edgar | Mob: 07980 541 893 / 07407 804 654 / 07884 664 686 | |
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis? for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.